Barely Significant
← all phrases

“showed a trend”

53,323 sentences · 53,323 papers · 65,371 search hits before verification

In the literature

showed a trendP =0.081.6× alpha
Two RCTs showed similar efficacy between EBL and EVO for treating GOV1 bleeding [ 201 , 231 ], another RCT showed a trend toward higher hemostasis rate in the EVO group compared to the EBL group (85% vs. 43%, P =0.08) [ 44 ].
Prevention and management of gastroesophageal varices.
Clin Mol Hepatol · 2018 · PMC5875194
showed a trendp = 0.0801.6× alpha
This might be partially due to the BO-Condition showing large RT-differences between regular and deviant trials from Block 1 on [ F (1, 37) = 17.68, p < 0.001, η p 2 = 0.323] whereas the RO- Condition merely showed a trend of an increasing difference between regular and deviant trials, when comparing Block 1 with Block 6 [ F (1, 37) = 3.24, p = 0.080, η p 2 = 0.081].
showed a trendP = 0.081.6× alpha
mRNA expression of collagen type I α 1 chain (COL1A1) showed a trend in being up-regulated following TGF-β1 treatment with mean FC = 4.8 ( P = 0.08) for control fibroblasts ( Figure 6 L) and mean FC = 6.6 ( P = 0.09) for IPF fibroblasts ( Figure 6 L) compared with corresponding untreated fibroblasts (FC = 1). α-Smooth muscle actin (encoded by gene ACTA2 ), a component of the cytoskeleton, is a marker of fibroblast activation to a contractile, ECM-producing phenotype.
showed a trendP =0.081.6× alpha
Both edoxaban doses demonstrated noninferiority to VKA in reducing the risk of stroke or SE in the primary analysis, including patients in the intent-to-treat population who received study drug during the treatment period (annual rates of 1.61%, 1.18%, and 1.50% for low-dose edoxaban, high-dose edoxaban, and warfarin, respectively); high-dose edoxaban showed a trend toward better efficacy vs warfarin in a prespecified superiority analysis of the intent-to-treat population during the entire study period (1.57% vs 1.80%; P =0.08). 29 In Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE), 18,201 patients (mean CHADS 2 score 2.1; median age 70 years) were randomized to apixaban 5 mg twice daily (2.5 mg doses were used in patients with two or more of the following: age ≥80 years, body weight ≤60 kg, or serum creatinine level ≥1.5 mg/dL) or warfarin.
showed a trendp = 0.081.6× alpha
When stratified by the median of age (w-GRS*age p = 0.001 and p = 0.02 for SNP group#1 and #2, respectively) individuals older than 54 years old had 0.23 BMI unit increase per additional risk allele and an explained BMI variability of 2.74% whereas those at 54 years or younger showed a trend of 0.10 units increase and 0.56% of explained BMI variability after multiple test correction (p = 0.08).